Abstract:Background: Botulinum toxin (BTX) is an effective management method for spasticity in children with cerebral palsy (CP), but the short- medium- and long-term effects remain unclear. Objective: The primary objective was to quantify the effects of BTX injections on upper limb spasticity over time in children with CP. The secondary objective was to evaluate efficacy according to the International Classification of Functioning, Disability, and Health-Children & Youth version framework. Methods: We conducted a systematic review and meta-analysis of randomized controlled trials that included control/comparison groups treated with a placebo or other treatments. We searched CINAHL, Embase, PubMed, Scopus, Web of Science, and PsycINFO from their inception to April 2024. The pooled mean difference (MD) or standard mean difference (SMD) with 95 % CI was calculated using a random effects model at the short-term (up to 3 months), medium-term (3 to 6 months), and long-term (over 6 months). Results: A total of 658 children with CP aged 1.8 to 19 years old in 12 eligible trials were involved. The primary outcome of the Melbourne Assessment percentile showed a significant increase in the medium- (MD = 2.63, 95 % CI 0.22 to 5.04, I² = 0 %) and long-term (MD = 4.72, 95 % CI 0.93 to 8.51, I² = 0 %) in favor of BTX. Pooled effects also showed that BTX significantly improved Modified Ashworth Scale scores in the short- (MD = -0.44, 95 % CI -0.88 to -0.01, I² = 88 %) and medium-term (MD = -0.20, 95 % CI -0.28 to -0.13, I² = 0 %), and individual goals and bimanual performance up to 6-months. No significantly higher risk of adverse events was observed with BTX. Conclusions and implications: BTX injections sustainably improved the quality of affected upper limb function and temporarily improved individual goals and bimanual performance in children with CP. Our findings cautiously support a time interval of 3 to 6 months between BTX injections in the upper limbs of children with CP. Trial registration: This study was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (Registration ID: CRD42022323672).

Efficacy and safety of serial injections of botulinum toxin A in children with spastic cerebral palsy

Effectiveness of Ultrasound-Guided Botulinum Toxin Injection Combined with Orthosis Training in the Treatment of Lower Limb Spasticity

Short- medium- and long-term effects of botulinum toxin on upper limb spasticity in children with cerebral palsy: A meta-analysis of randomized controlled trials

The Effect of Different Localizing Techniques in Guiding Botulinum Toxin Injection in the Treatment of Lower Limb Spasticity in Cerebral Palsy Children

High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy

Botulinum Toxin-A in Children With Congenital Spastic Hemiplegia Does Not Improve Upper Extremity Motor-Related Function Over Rehabilitation Alone: A Randomized Controlled Trial

Effects of botulinum toxin A on calf muscles in children with cerebral palsy: a systematic review

Effect of combined rehabilitation program with botulinum toxin type A injections on gross motor function scores in children with spastic cerebral palsy

Intrathecal Baclofen Infusion-Botulinum Toxin Combined Treatment Efficacy in the Management of Spasticity due to Cerebral Palsy

[Clinical experience of the repeated multilevel injections of the botulinum toxin type A (abobotulinum toxin A) in the spastic forms of cerebral palsy].

LONG-TERM REPEATED BOTULINUM TOXIN A TREATMENT OVER 12 YEARS GRADUALLY CHANGES GAIT CHARACTERISTICS: SINGLE-CASE STUDY

Therapeutic Use of Botulinum Toxin in Neurorehabilitation

The effect of botulinum toxin type-A injection on spasticity, range of motion and gait patterns in children with spastic diplegic cerebral palsy: an Egyptian study

Short-Term Effects of Botulinum Toxin-A Injection on the Medial Gastrocnemius Histological Features in Ambulant Children with Cerebral Palsy: A Longitudinal Pilot Study

Exploration of Effect and Dosage of Botulinum Toxin Type A for Long-Term Treatment of Idiopathic Blepharospasm

The efficacy and safety of using botulinum toxin type A in treating spasticity resulting from stroke or traumatic brain injury: A systematic review with meta-analysis

A Systematic Review of Botulinum Toxin Injection in Pediatric Dystonia

Treatment of spasticity in spinal cord injury with botulinum toxin

Botulinum toxin type A injections for treatment of spastic equinus in cerebral palsy: a secondary analysis of factors predictive of favorable response

Long-term effect of botulinum toxin A on the hip and spine in cerebral palsy: A national retrospective cohort study in Taiwan

Influence of Injection of Chinese Botulinum Toxin Type A on the Histomorphology and Myosin Heavy Chain Composition of Rat Gastrocnemius Muscles.